MEHRZAD SERAJI: Open Payments
NPI 1942539085 · SAINT LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,337 in 59 payments from 19 companies in 2025. Trend: 2023 $630 · 2024 $746 · 2025 $1,337
Food & beverage: $1,226Education: $111
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 12 | $182 |
| ABBVIE INC. | 6 | $160 |
| Teva Pharmaceuticals USA, Inc. | 4 | $155 |
| Supernus Pharmaceuticals, Inc. | 5 | $114 |
| Alkermes, Inc. | 5 | $113 |
| Axsome Therapeutics, Inc. | 5 | $95 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $83 |
| Janssen Pharmaceuticals, Inc | 2 | $77 |
| Otsuka America Pharmaceutical, Inc. | 3 | $65 |
| Collegium Pharmaceutical, Inc. | 2 | $43 |
Products named: INGREZZA, VRAYLAR, Qelbree, ARISTADA, Auvelity, CAPLYTA, REXULTI, INVEGA SUSTENNA.
Industry payments across MO — which companies pay providers there.
